Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03373760
Title Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications
Therapies
Age Groups: child | senior | adult
Covered Countries USA


No variant requirements are available.